Oaktree Acquisition Corp III Life Sciences-A 2026年季度报告

For the quarter ended March 31, 2026 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF1934 For the transition period fromtoCommission file number:001-42383 OAKTREE ACQUISITION CORP. III LIFE SCIENCES 98-1799512(I.R.S. EmployerIdentification No.) Cayman Islands(State or other jurisdiction ofincorporation or organization) 333 South Grand Avenue, 28th FloorLos Angeles, California 90071(Address of principal executive offices)+1(213)830-6300(Issuer’s telephone number) Securities registered pursuant to Section12(b) of the Act: TradingSymbol(s)OACCU Title of each classUnits, each consisting of one Class A ordinaryshare, $0.0001 par value, and one-fifth of oneredeemable warrantClass A ordinary shares included as part of theunitsRedeemable warrants included as part of theunits, each whole warrant exercisable for oneClass A ordinary share at an exercise price of$11.50 Check whether the issuer (1)filed all reports required to be filed by Section13 or 15(d) of the Exchange Act during the past 12 months (or for suchshorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or anemerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growthcompany” in Rule12b-2 of the Exchange Act. Acceleratedfiler☐Smallerreportingcompany☒Emerging growth company☒ Largeacceleratedfiler☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☒No☐ As of May13, 2026, there were 19,783,010 ClassA ordinary shares, $0.0001 par value and 4,799,758 ClassB ordinary shares, $0.0001 par value, issuedand outstanding. Table of Contents OAKTREE ACQUISITION CORP. III LIFE SCIENCESFORM 10-Q FOR THE QUARTER ENDED MARCH31, 2026TABLE OF CONTENTS Part I. Financial InformationItem 1. Interim Financial StatementsCondensed Balance Sheets as of March31, 2026 (Unaudited) and December31, 2025Condensed Statements of Operations for the three months ended March31, 2026 and 2025 (Unaudited)Condensed Statements of Changes in Shareholders’ Deficit for the three months ended March31, 2026 and 2025 (Unaudited)Condensed Statements of Cash Flows for the three months ended March31, 2026 and 2025 (Unaudited)Notes to Condensed Financial Statements (Unaudited)Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 4. Controls and ProceduresPart II. Other InformationItem 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales of Equity Securities and Use of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mine Safety DisclosuresItem 5. Other InformationItem 6. ExhibitsPart III. Signatures Table of Contents PART I - FINANCIAL INFORMATION OAKTREE ACQUISITION CORP. III LIFE SCIENCESCONDENSED BALANCE SHEETS OAKTREE ACQUISITION CORP. III LIFE SCIENCESCONDENSED STATEMENTS OF OPERATIONS(UNAUDITED) For the Three Months EndedMarch31,20262025General and administrative expenses$456,538$444,802Loss from operations(456,538)(444,802)Other income:Interest earned on cash held in Trust Account1,850,6592,103,593Total other income1,850,6592,103,593Net income$1,394,121$1,658,791Weighted average shares outstanding of redeemable ClassA ordinary shares19,199,02919,199,029Basic and diluted net income per share, ClassA ordinary shares$0.06$0.07Weighted average shares outstanding of non-redeemable ClassA and B ordinary shares5,383,7385,383,738Basic and diluted net income per share, non-redeemable ClassA ordinary shares and ClassB ordinary shares$0.06$0.07 Table of Contents OAKTREE ACQUISITION CORP. III LIFE SCIENCESCONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT(UNAUDITED) FOR THE THREE MONTHS ENDED MARCH31, 2026 OAKTREE ACQUISITION CORP. III LIFE SCIENCESCONDENSED STATEMENTSOF CASH FLOWS(UNAUDITED) For the Three Months EndedMarch31,20262025Cash Flows from Operating Activities:Net income$1,394,121$1,658,791Adjustments to reconcile net income to net cash used in operating activities:Interest earned on cash held in Trust Account(1,850,659)(2,103,593)Changes in op